MSH3 and head and neck squamous cell carcinoma: MSH3 rs26279 altered radiosensitivity in breast cancer patients [13], response to platinum-based therapy and survival in lung cancer patients [9], response to CDDP chemoradiation and hematological toxicity in a unique case of laryngeal cancer [15] and survival in HNSCC patients treated by CDDP and RT [20], but its roles in nephrotoxicity and ototoxicity were not described in studies.